Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Chaperone Hsp70 can cross the plasma membrane of living cells using mechanisms that so far have not received much research attention. Searching the part of the molecule that is responsible for transport ability of Hsp70, we found a cationic sequence composed of 20 amino acid residues on its surface,
KST
peptide, which was used in further experiments. We showed that
KST
peptide enters living cells of various origins with the same efficiency as the full-length chaperone.
KST
peptide is capable of carrying cargo with a molecular weight 30 times greater than its own into cells. When we compared the membrane-crossing activity of
KST
peptide in complex with Avidin (
KST
-Av complex) with that of similarly linked canonical
TAT
peptide, we found that
TAT
peptide penetrated SK-N-SH human neuroblastoma cells at a similar rate and efficiency as the
KST
peptide. Furthermore,
KST
peptide can carry protein complexes consisting of a specific antibody coupled to the peptide through the Avidin bridge. An antibody to Hsp70 delivered to SK-N-SH cells with high expression level of Hsp70 reduced the protective power of the chaperone and sensitized the cells to the pro-apoptotic effect of staurosporine. We studied the mechanisms of penetration of
KST
-Av and full-length Hsp70 inside human neuroblastoma SK-N-SH and human erythroleukemia K-562 cells and found that both used an active intracellular transport mechanism that included vesicular structures and negatively charged lipid membrane domains. Competition analysis of intracellular transport showed that the chaperone reduced intracellular penetration of
KST
peptide and conversely
KST
peptide prevented Hsp70 transport in a dose-dependent manner.
...
PMID:The discovery of Hsp70 domain with cell-penetrating activity. 2538 97